International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy.
作者信息
Mancuso Michelangelo, McFarland Robert, Klopstock Thomas, Hirano Michio
机构信息
Department of Experimental and Clinical Medicine, Neurological Institute, University of Pisa, Italy.
Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Department of Physiology and Functional Genomics NE1 3BZ, Newcastle University, Newcastle upon Tyne, UK.
出版信息
Neuromuscul Disord. 2017 Dec;27(12):1126-1137. doi: 10.1016/j.nmd.2017.08.006. Epub 2017 Sep 8.
Abstract
摘要
相似文献
1
International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy.
Neuromuscul Disord. 2017 Dec;27(12):1126-1137. doi: 10.1016/j.nmd.2017.08.006. Epub 2017 Sep 8.
2
280th ENMC International Workshop: The ERN EURO-NMD mitochondrial diseases working group; diagnostic criteria and outcome measures in primary mitochondrial myopathies. Hoofddorp, the Netherlands, 22-24 November 2024.
Neuromuscul Disord. 2025 May;50:105340. doi: 10.1016/j.nmd.2025.105340. Epub 2025 Mar 22.
3
Outcome measures for children with mitochondrial disease: consensus recommendations for future studies from a Delphi-based international workshop.
J Inherit Metab Dis. 2018 Nov;41(6):1267-1273. doi: 10.1007/s10545-018-0229-5. Epub 2018 Jul 19.
4
1st International Workshop on Clinical trial readiness for sarcoglycanopathies 15-16 November 2016, Evry, France.
Neuromuscul Disord. 2017 Jul;27(7):683-692. doi: 10.1016/j.nmd.2017.02.011. Epub 2017 Mar 3.
5
Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop.
Am J Kidney Dis. 2020 Jul;76(1):109-120. doi: 10.1053/j.ajkd.2020.01.022. Epub 2020 May 12.
6
International workshop: what is needed to ensure outcome measures for Rett syndrome are fit-for-purpose for clinical trials? June 7, 2023, Nashville, USA.
Trials. 2024 Dec 21;25(1):845. doi: 10.1186/s13063-024-08678-6.
7
213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015.
Neuromuscul Disord. 2016 Aug;26(8):523-34. doi: 10.1016/j.nmd.2016.05.014. Epub 2016 May 27.
8
Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations.
Pain. 2006 Dec 5;125(3):208-215. doi: 10.1016/j.pain.2006.09.028. Epub 2006 Oct 25.
9
Research priorities for non-pharmacological therapies for common musculoskeletal problems: nationally and internationally agreed recommendations.
BMC Musculoskelet Disord. 2009 Jan 9;10:3. doi: 10.1186/1471-2474-10-3.
10
Consensus Recommendations for Clinical Outcome Assessments and Registry Development in Ataxias: Ataxia Global Initiative (AGI) Working Group Expert Guidance.
Cerebellum. 2024 Jun;23(3):924-930. doi: 10.1007/s12311-023-01547-z. Epub 2023 Apr 5.
引用本文的文献
1
The profound implications of mitochondrial myopathy on activities of daily living: an observational qualitative study of standardized structured and semi-structured patient interviews.
Ther Adv Chronic Dis. 2025 Jul 25;16:20406223251344763. doi: 10.1177/20406223251344763. eCollection 2025.
2
Open-label pilot study using hydroxytyrosol as dietary supplements in patients with mitochondrial diseases.
Orphanet J Rare Dis. 2025 Jun 6;20(1):283. doi: 10.1186/s13023-025-03795-0.
3
The most bothersome symptoms in neuromuscular diseases: the ERN EURO NMD Survey.
Orphanet J Rare Dis. 2025 May 8;20(1):221. doi: 10.1186/s13023-025-03742-z.
4
GDF15 Neutralization Ameliorates Muscle Atrophy and Exercise Intolerance in a Mouse Model of Mitochondrial Myopathy.
J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13715. doi: 10.1002/jcsm.13715.
5
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.
Orphanet J Rare Dis. 2024 Nov 21;19(1):431. doi: 10.1186/s13023-024-03421-5.
6
Resolving Phenotypic Variability in Mitochondrial Diseases: Preliminary Findings of a Proteomic Approach.
Int J Mol Sci. 2024 Oct 5;25(19):10731. doi: 10.3390/ijms251910731.
7
Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group.
Eur J Neurol. 2024 Jul;31(7):e16275. doi: 10.1111/ene.16275. Epub 2024 Apr 4.
8
A clinical approach to diagnosis and management of mitochondrial myopathies.
Neurotherapeutics. 2024 Jan;21(1):e00304. doi: 10.1016/j.neurot.2023.11.001. Epub 2023 Dec 19.
9
Characterization of Fatigue in Primary Mitochondrial Myopathies: Findings From a Qualitative Interview Study.
Neurol Clin Pract. 2024 Feb;14(1):e200229. doi: 10.1212/CPJ.0000000000200229. Epub 2023 Dec 22.
10
Mitochondrial myopathy without extraocular muscle involvement: a unique clinicopathologic profile.
J Neurol. 2024 Feb;271(2):864-876. doi: 10.1007/s00415-023-12005-5. Epub 2023 Oct 17.
本文引用的文献
1
Quantification of gait in mitochondrial m.3243A > G patients: a validation study.
Orphanet J Rare Dis. 2017 May 15;12(1):91. doi: 10.1186/s13023-017-0644-y.
2
Common data elements for clinical research in mitochondrial disease: a National Institute for Neurological Disorders and Stroke project.
J Inherit Metab Dis. 2017 May;40(3):403-414. doi: 10.1007/s10545-017-0035-5. Epub 2017 Mar 16.
3
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool.
PLoS One. 2017 Feb 21;12(2):e0172346. doi: 10.1371/journal.pone.0172346. eCollection 2017.
4
Domains of Daily Physical Activity in Children with Mitochondrial Disease: A 3D Accelerometry Approach.
JIMD Rep. 2017;36:7-17. doi: 10.1007/8904_2016_35. Epub 2017 Jan 17.
5
The 6-min mastication test: a unique test to assess endurance of continuous chewing, normal values, reliability, reproducibility and usability in patients with mitochondrial disease.
J Oral Rehabil. 2017 Mar;44(3):155-162. doi: 10.1111/joor.12481. Epub 2017 Jan 30.
6
Toward a therapy for mitochondrial disease.
Biochem Soc Trans. 2016 Oct 15;44(5):1483-1490. doi: 10.1042/BST20160085.
7
Dynamic P-MRSI using spiral spectroscopic imaging can map mitochondrial capacity in muscles of the human calf during plantar flexion exercise at 7 T.
NMR Biomed. 2016 Dec;29(12):1825-1834. doi: 10.1002/nbm.3662. Epub 2016 Nov 8.
8
Preliminary Evaluation of Clinician Rated Outcome Measures in Mitochondrial Disease.
J Neuromuscul Dis. 2015 Jun 4;2(2):151-155. doi: 10.3233/JND-140061.
9
FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders.
Neurology. 2016 Nov 29;87(22):2290-2299. doi: 10.1212/WNL.0000000000003374. Epub 2016 Oct 28.
10
Mitochondrial diseases.
Nat Rev Dis Primers. 2016 Oct 20;2:16080. doi: 10.1038/nrdp.2016.80.
Zotero 插件